Breast Cancer Clinical Trial
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Summary
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Eligibility Criteria
Inclusion Criteria:
Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.
Women of childbearing potential must agree to remain abstinent or use contraception, and agree to refrain from donating eggs during the treatment period and after the final dose of study treatment as specified in the protocol.
Men who are not surgically sterile must agree to remain abstinent or use a condom, and agreement to refrain from donating sperm during the treatment period and after the final dose of study treatment as specified in the protocol.
Exclusion Criteria:
Active brain metastases.
Malabsorption or other condition that interferes with enteral absorption.
Clinically significant cardiovascular dysfunction or liver disease.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 60 Locations for this study
Duarte California, 91010, United States
La Jolla California, 92093, United States
Orange California, 92868, United States
San Francisco California, 94115, United States
New Haven Connecticut, 06520, United States
Sarasota Florida, 34232, United States
Boston Massachusetts, 02215, United States
New York New York, 10065, United States
Oklahoma City Oklahoma, 73104, United States
Philadelphia Pennsylvania, 19104, United States
Pittsburgh Pennsylvania, 15232, United States
Darlinghurst New South Wales, 2010, Australia
Melbourne Victoria, 3004, Australia
North Melbourne Victoria, 3051, Australia
Nedlands Western Australia, 6009, Australia
Edegem , 2650, Belgium
Herstal , 4040, Belgium
Mechelen , 2800, Belgium
Sao Jose Do Rio Preto SP, 15090, Brazil
Ottawa Ontario, K1H 8, Canada
Toronto Ontario, M5G 1, Canada
Montreal Quebec, H2W 1, Canada
Haifa , 31096, Israel
Ramat-Gan , 52620, Israel
Tel Aviv , 64239, Israel
Meldola Emilia-Romagna, 47014, Italy
Milano Lombardia, 20132, Italy
Milano Lombardia, 20162, Italy
Rozzano (MI) Lombardia, 20089, Italy
Pisa Toscana, 56100, Italy
Seongnam-si , 13605, Korea, Republic of
Seoul , 03080, Korea, Republic of
Seoul , 05505, Korea, Republic of
Seoul , 06351, Korea, Republic of
Amsterdam , 1066 , Netherlands
Leiden , 2333 , Netherlands
Maastricht , 6229 , Netherlands
Utrecht , 3584 , Netherlands
Auckland , 1023, New Zealand
Christchurch , 8011, New Zealand
Bergen , 5053, Norway
Oslo , 0424, Norway
Gdansk , 80-95, Poland
Jozefow , 05-41, Poland
Poznań , 60-78, Poland
Kazan Tatarstan, 42002, Russian Federation
Barcelona , 08035, Spain
Madrid , 28040, Spain
Madrid , 28041, Spain
Madrid , 28050, Spain
Malaga , 29010, Spain
Sevilla , 41013, Spain
Valencia , 46010, Spain
Basel , 4031, Switzerland
Bern , 3010, Switzerland
Genève , 1211, Switzerland
Zürich , 8091, Switzerland
Cardiff , CF14 , United Kingdom
London , W1T 7, United Kingdom
Manchester , M20 4, United Kingdom
How clear is this clinincal trial information?